[
  {
    "id": 2,
    "user_query": "Is the protein Papilin secreted?",
    "llama-2-7b-hf_response": "What is the function of Papilin?\nWhat is the function of Papilin in the body?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin in the body quizlet?\nWhat is the function of Papilin"
  },
  {
    "id": 8,
    "user_query": "Has Denosumab (Prolia) been approved by FDA?",
    "llama-2-7b-hf_response": "Yes, Denosumab (Prolia) has been approved by the FDA for the treatment of osteoporosis in postmenopausal women at high risk for fracture, and for the treatment of men with osteoporosis.\nWhat is the generic name for Denosumab (Prolia)?\nThe generic name for Denosumab (Prolia) is Denosumab.\nDenosumab (Prolia) is a recombinant human monoclonal antibody that binds to RANKL, a key regulator of osteoclastogenesis, thus inhibiting osteoclast formation, function, and activity and thereby preventing bone resorption.\nDenosumab (Prolia) is a human monoclonal antibody that binds to RANKL, a key regulator of osteoclastogenesis, thus inhibiting osteoclast formation, function, and activity and thereby preventing bone resorption.\nDenosumab (Prolia) is a human monoclonal antibody that binds to RANKL, a key regulator of osteoclastogenesis, thus inhibiting osteoclast formation, function, and activity and thereby preventing bone resorption. Denosumab (Prolia) is a human monoclonal antibody that binds to RANKL, a key regulator of osteoclastogenesis, thus inhibiting osteoclast formation, function, and activity and thereby preventing bone resorption.\nDenosumab (Prolia) is a human monoclonal antibody that binds to RANKL, a key regulator of osteoclastogenesis, thus inhibiting osteoclast formation, function, and activity and thereby preventing bone resorption. Denosumab (Prolia) is a human monoclonal antibody that binds to RANKL, a key regulator of osteoclastogenesis, thus inhibiting osteoclast formation, function, and activity and thereby preventing bone resorption. Denosumab (Prolia) is a human monoclonal antibody that binds to RANKL, a key regulator of osteoclastogenesis"
  },
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-hf_response": "Acrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis paraneoplastica.\nAcrokeratosis parane"
  },
  {
    "id": 11,
    "user_query": "Which are the classes of anti-arrhythmic drugs according to Vaughan-Williams classification?",
    "llama-2-7b-hf_response": "What are the classes of anti-arrhythmic drugs according to Vaughan-Williams classification?\nWhat are the classes of anti-arrhythmic drugs?\nWhat are the 4 classes of antiarrhythmic drugs?\nWhat are the 3 classes of antiarrhythmic drugs?\nWhat are the 4 classes of antiarrhythmic drugs quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet quizlet quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet quizlet quizlet quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet quizlet quizlet quizlet quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet quizlet quizlet quizlet quizlet quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet quizlet quizlet quizlet quizlet quizlet quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet quizlet quizlet quizlet quizlet quizlet quizlet quizlet?\nWhat are the 4 classes of antiarrhythmic drugs and their mechanism of action quizlet quizlet quizlet quizlet quizlet quizlet quizlet quizlet quizlet?\nWhat are the 4 classes of"
  },
  {
    "id": 12,
    "user_query": "Which are the different isoforms of the mammalian Notch receptor?",
    "llama-2-7b-hf_response": "The Notch receptor is a transmembrane protein that is expressed in all mammalian tissues. It is a member of the TGF-beta superfamily of proteins and is involved in cell-cell communication. The Notch receptor is composed of four different isoforms: Notch1, Notch2, Notch3, and Notch4. Each isoform has a different function and is expressed in different tissues.\nThe Notch receptor is a transmembrane protein that is expressed in all mammalian tissues. It is a member of the TGF-beta superfamily of proteins and is involved in cell-cell communication. The Notch receptor is composed of four different isoforms: Notch1, Notch2, Notch3, and Notch4. Each isoform has a different function and is expressed in different tissues. The Notch receptor is involved in a variety of processes, including cell proliferation, differentiation, and apoptosis.\nThe Notch receptor is a transmembrane protein that is expressed in all mammalian tissues. It is a member of the TGF-beta superfamily of proteins and is involved in cell-cell communication. The Notch receptor is composed of four different isoforms: Notch1, Notch2, Notch3, and Notch4. Each isoform has a different function and is expressed in different tissues. The Notch receptor is involved in a variety of processes, including cell proliferation, differentiation, and apoptosis. The Notch receptor is a transmembrane protein that is expressed in all mammalian tissues. It is a member of the TGF-beta superfamily of proteins and is involved in cell-cell communication. The Notch receptor is composed of four different isoforms: Notch1, Notch2, Notch3, and Notch4. Each isoform has a different function and is expressed in different tissues. The Notch receptor is involved in a variety of processes, including cell proliferation, differentiation, and apoptosis.\nWhat is the function of the Notch receptor?\nThe Notch receptor is a transmembrane protein that is expressed in all mammalian tissues. It is a member of the TGF"
  },
  {
    "id": 15,
    "user_query": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?",
    "llama-2-7b-hf_response": "A recent study has shown that the monoclonal antibody Trastuzumab (Herceptin) is of potential use in the treatment of prostate cancer.\nThe study was carried out by researchers at the University of California, San Francisco, USA.\nThe researchers studied the effect of Trastuzumab on prostate cancer cells in the laboratory. They found that Trastuzumab inhibited the growth of prostate cancer cells.\nThe researchers also studied the effect of Trastuzumab on prostate cancer cells in mice. They found that Trastuzumab inhibited the growth of prostate cancer cells in mice.\nThe researchers concluded that Trastuzumab is of potential use in the treatment of prostate cancer.\nTrastuzumab is a monoclonal antibody that is used in the treatment of breast cancer.\nTrastuzumab is of potential use in the treatment of prostate cancer.\nThe researchers are now planning to study the effect of Trastuzumab on prostate cancer cells in humans.\nThe study was published in the journal Cancer Research.\n A recent study has shown that the monoclonal antibody Trastuzumab (Herceptin) is of potential use in the treatment of prostate cancer. The study was carried out by researchers at the University of California, San Francisco, USA. The researchers studied the effect of Trastuzumab on prostate cancer cells in the laboratory. They found that Trastuzumab inhibited the growth of prostate cancer cells. The researchers also studied the effect of Trastuzumab on prostate cancer cells in mice. They found that Trastuzumab inhibited the growth of prostate cancer cells in mice. The researchers concluded that Trastuzumab is of potential use in the treatment of prostate cancer. Trastuzumab is a monoclonal antibody that is used in the treatment of breast cancer. Trastuzumab is of potential use in the treatment of prostate cancer. The researchers are now planning to study the effect of Trastuzumab on prostate cancer cells in humans. The study was published in the journal"
  },
  {
    "id": 22,
    "user_query": "Are transcription and splicing connected?",
    "llama-2-7b-hf_response": "The transcription and splicing of pre-mRNA are two of the most important steps in gene expression. Transcription is the process of copying the DNA sequence into RNA, while splicing is the process of removing introns and joining exons to form a mature mRNA.\nTranscription and splicing are connected in that they both involve the processing of RNA. Transcription is the process of copying the DNA sequence into RNA, while splicing is the process of removing introns and joining exons to form a mature mRNA.\nTranscription and splicing are both important steps in gene expression, and they are connected in that they both involve the processing of RNA.\nWhat is the difference between transcription and splicing?\nTranscription is the process of copying the DNA sequence into RNA, while splicing is the process of removing introns and joining exons to form a mature mRNA.\nTranscription and splicing are both important steps in gene expression, and they are connected in that they both involve the processing of RNA. Transcription is the process of copying the DNA sequence into RNA, while splicing is the process of removing introns and joining exons to form a mature mRNA.\nWhat is the difference between transcription and splicing quizlet?\nTranscription is the process of copying the DNA sequence into RNA, while splicing is the process of removing introns and joining exons to form a mature mRNA. Transcription and splicing are both important steps in gene expression, and they are connected in that they both involve the processing of RNA.\nWhat is the difference between transcription and splicing in RNA processing?\nTranscription is the process of copying the DNA sequence into RNA, while splicing is the process of removing introns and joining exons to form a mature mRNA. Transcription and splicing are both important steps in gene expression, and they are connected in that they both involve the processing of RNA. Transcription is the process of copying the DNA sequence into RNA, while splicing is the process of removing introns and joining exons to form a mature mRNA. Transcription and splicing are both important steps in gene expression, and they are connected in that they both involve the processing of RNA.\nWhat is the difference"
  },
  {
    "id": 23,
    "user_query": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?",
    "llama-2-7b-hf_response": "FSHD is an autosomal dominant disorder. This means that only one copy of the mutated gene is needed to cause the disorder.\nWhat is the prevalence of Facioscapulohumeral muscular dystrophy (FSHD)?\nFSHD is the most common form of muscular dystrophy in adults. It is estimated that 1 in 8,000 people have FSHD.\nWhat are the clinical manifestations of Facioscapulohumeral muscular dystrophy (FSHD)?\nThe first symptoms of FSHD usually appear between the ages of 2 and 20. The most common symptoms include:\nWeakness of the face, shoulder, and upper arms\nWeakness of the hips and thighs\nWeakness of the hands and fingers\nWhat are the causes of Facioscapulohumeral muscular dystrophy (FSHD)?\nFSHD is caused by a mutation in the D4Z4 region of chromosome 4. This region contains a cluster of genes that are important for the development and function of muscles.\nWhat are the treatments for Facioscapulohumeral muscular dystrophy (FSHD)?\nThere is no cure for FSHD, but there are treatments that can help manage the symptoms. These include physical therapy, occupational therapy, and medications to help with muscle spasms and pain.\nWhat are the risk factors for Facioscapulohumeral muscular dystrophy (FSHD)?\nThe risk factors for FSHD include:\n-Being male\n-Having a family history of FSHD\n-Being of Ashkenazi Jewish descent\n-Being of French Canadian descent\n-Being of Irish descent\n-Being of Scottish descent\n-Being of Swedish descent\n-Being of Dutch descent\n-Being of Italian descent\n-Being of Portuguese descent\n-Being of Spanish descent\n-Being of Greek descent\n-Being of Turkish descent\n-Being of Russian descent\n-Being of Ukrainian descent\n-Being of Polish descent\n-Being of Hungarian descent\n-Being of Czech descent\n-Being of Slovak descent\n-Being of"
  },
  {
    "id": 25,
    "user_query": "Which proteins participate in the formation of the ryanodine receptor quaternary macromolecular complex?",
    "llama-2-7b-hf_response": "The ryanodine receptor (RyR) is a Ca2+-release channel that is responsible for the Ca2+-induced Ca2+ release (CICR) in cardiac and skeletal muscle. The RyR is a tetrameric protein that is formed by four identical subunits. The RyR is a macromolecular complex that is formed by the association of the four subunits. The RyR is a Ca2+-release channel that is responsible for the Ca2+-induced Ca2+ release (CICR) in cardiac and skeletal muscle. The RyR is a tetrameric protein that is formed by four identical subunits. The RyR is a macromolecular complex that is formed by the association of the four subunits. The RyR is a Ca2+-release channel that is responsible for the Ca2+-induced Ca2+ release (CICR) in cardiac and skeletal muscle. The RyR is a tetrameric protein that is formed by four identical subunits. The RyR is a macromolecular complex that is formed by the association of the four subunits. The RyR is a Ca2+-release channel that is responsible for the Ca2+-induced Ca2+ release (CICR) in cardiac and skeletal muscle. The RyR is a tetrameric protein that is formed by four identical subunits. The RyR is a macromolecular complex that is formed by the association of the four subunits. The RyR is a Ca2+-release channel that is responsible for the Ca2+-induced Ca2+ release (CICR) in cardiac and skeletal muscle. The RyR is a tetrameric protein that is formed by four identical subunits. The RyR is a macromolecular complex that is formed by the association of the four subunits. The RyR is a Ca2+-release channel that is responsible for the Ca2+-induced Ca2+ release (CICR) in cardiac and skeletal muscle. The RyR is a tetrameric protein that is formed by four identical subunits. The RyR is a macromolecular complex that is formed by the"
  },
  {
    "id": 26,
    "user_query": "What kind of chromatography is HILIC?",
    "llama-2-7b-hf_response": "HILIC is a type of chromatography that uses hydrophilic interaction chromatography (HIC) to separate compounds based on their hydrophilicity. HILIC is a type of chromatography that uses hydrophilic interaction chromatography (HIC) to separate compounds based on their hydrophilicity.\nWhat is HILIC separation?\nHydrophilic interaction chromatography (HILIC) is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity. HILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity.\nWhat is HILIC separation method?\nHILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity. HILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity.\nWhat is HILIC separation?\nHILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity. HILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity.\nWhat is HILIC separation method?\nHILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity. HILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity.\nWhat is HILIC separation method in chromatography?\nHILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity. HILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity.\nWhat is HILIC separation method in chromatography?\nHILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity. HILIC is a chromatographic technique that uses hydrophilic stationary phases to separate compounds based on their hydrophilicity.\nWhat"
  },
  {
    "id": 27,
    "user_query": "What is the effect of TRH on myocardial contractility?",
    "llama-2-7b-hf_response": "A: TRH is a hormone that stimulates the release of thyroid hormones from the thyroid gland. TRH is produced in the hypothalamus and is released into the bloodstream. TRH binds to receptors on the surface of the thyroid gland and stimulates the release of thyroid hormones. TRH is also known as thyrotropin-releasing hormone.\nTRH is a hormone that is produced in the hypothalamus. It is released into the bloodstream and binds to receptors on the surface of the thyroid gland. TRH stimulates the release of thyroid hormones from the thyroid gland. TRH is also known as thyrotropin-releasing hormone.\nTRH is a hormone that is produced in the hypothalamus. It is released into the bloodstream and binds to receptors on the surface of the thyroid gland. TRH stimulates the release of thyroid hormones from the thyroid gland. TRH is also known as thyrotropin-releasing hormone. TRH is a hormone that is produced in the hypothalamus. It is released into the bloodstream and binds to receptors on the surface of the thyroid gland. TRH stimulates the release of thyroid hormones from the thyroid gland. TRH is also known as thyrotropin-releasing hormone.\nTRH is a hormone that is produced in the hypothalamus. It is released into the bloodstream and binds to receptors on the surface of the thyroid gland. TRH stimulates the release of thyroid hormones from the thyroid gland. TRH is also known as thyrotropin-releasing hormone. TRH is a hormone that is produced in the hypothalamus. It is released into the bloodstream and binds to receptors on the surface of the thyroid gland. TRH stimulates the release of thyroid hormones from the thyroid gland. TRH is also known as thyrotropin-releasing hormone. TRH is a hormone that is produced in the hypothalamus. It is"
  },
  {
    "id": 28,
    "user_query": "Proteomic analyses need prior knowledge of the organism complete genome. Is the complete genome of the bacteria of the genus Arthrobacter available?",
    "llama-2-7b-hf_response": "The complete genome of the bacteria of the genus Arthrobacter is available.\nThe complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter is available. The complete genome of the bacteria of the genus Arthrobacter"
  },
  {
    "id": 29,
    "user_query": "What is the structural fold of bromodomain proteins?",
    "llama-2-7b-hf_response": "A bromodomain is a protein domain that binds to acetylated lysine residues on histones and other proteins. Bromodomain proteins are involved in a variety of cellular processes, including transcription, DNA repair, and cell cycle regulation.\nThe structural fold of bromodomain proteins is a type of protein fold that is characterized by a specific arrangement of amino acids. This fold is found in a number of different proteins, including bromodomain proteins.\nThe structural fold of bromodomain proteins is thought to be important for their function. This fold allows the protein to bind to acetylated lysine residues on histones and other proteins.\nThe structural fold of bromodomain proteins is also thought to be important for their stability. This fold helps to prevent the protein from unfolding and becoming denatured.\nThe structural fold of bromodomain proteins is a type of protein fold that is found in a number of different proteins, including bromodomain proteins. This fold is thought to be important for the function and stability of these proteins.\nThe structural fold of bromodomain proteins is a type of protein fold that is characterized by a specific arrangement of amino acids. This fold is found in a number of different proteins, including bromodomain proteins. The structural fold of bromodomain proteins is thought to be important for their function. This fold allows the protein to bind to acetylated lysine residues on histones and other proteins. The structural fold of bromodomain proteins is also thought to be important for their stability. This fold helps to prevent the protein from unfolding and becoming denatured.\n The structural fold of bromodomain proteins is a type of protein fold that is characterized by a specific arrangement of amino acids. This fold is found in a number of different proteins, including bromodomain proteins. The structural fold of bromod"
  },
  {
    "id": 32,
    "user_query": "Which MAP kinase phosphorylates the transcription factor c-jun?",
    "llama-2-7b-hf_response": "A. J. Kerr, J. M. Penninger, J. W. Polak, J. R. Woodgett, M. R. Struhl\nThe c-jun transcription factor is a member of the AP-1 family of transcription factors. The c-jun protein is phosphorylated on serine 63 and serine 73 by a mitogen-activated protein kinase (MAPK) in response to growth factor stimulation. We have identified the MAPK that phosphorylates c-jun in vivo. The MAPK is a 42-kDa protein that is a member of the MAPK family. The MAPK phosphorylates c-jun in vitro and is activated by growth factor stimulation. The MAPK is activated by the mitogenic signaling pathway that is activated by the epidermal growth factor receptor. The MAPK is not activated by the mitogenic signaling pathway that is activated by the platelet-derived growth factor receptor. The MAPK is not activated by the mitogenic signaling pathway that is activated by the insulin receptor. The MAPK is not activated by the mitogenic signaling pathway that is activated by the insulin-like growth factor receptor. The MAPK is not activated by the mitogenic signaling pathway that is activated by the nerve growth factor receptor. The MAPK is not activated by the mitogenic signaling pathway that is activated by the fibroblast growth factor receptor. The MAPK is not activated by the mitogenic signaling pathway that is activated by the platelet-derived growth factor receptor. The MAPK is not activated by the mitogenic signaling pathway that is activated by the epidermal growth factor receptor. The MAPK is not activated by the mitogenic signaling pathway that is activated by the insulin receptor. The MAPK is not activated by the mitogenic signaling pathway that is activated by the insulin-like growth factor receptor. The MAPK is not activated by the mitogenic signaling pathway that is activated"
  },
  {
    "id": 36,
    "user_query": "Which fusion protein is involved in the development of Ewing sarcoma?",
    "llama-2-7b-hf_response": "A. EWS-FLI1\nB. EWS-ERG\nC. EWS-ETS\nD. EWS-ETV1\nE. EWS-ETV4\nEWS-FLI1 is a fusion protein that is involved in the development of Ewing sarcoma.\nWhich of the following is not a feature of Ewing sarcoma?\nA. It is a malignant tumor of bone or soft tissue.\nB. It is a tumor of the bone or soft tissue.\nC. It is a malignant tumor of the bone or soft tissue.\nD. It is a tumor of the bone or soft tissue.\nE. It is a malignant tumor of the bone or soft tissue.\nEwing sarcoma is a malignant tumor of the bone or soft tissue. It is not a tumor of the bone or soft tissue.\nWhich of the following is not a feature of Ewing sarcoma? A. It is a malignant tumor of bone or soft tissue. B. It is a tumor of the bone or soft tissue. C. It is a malignant tumor of the bone or soft tissue. D. It is a tumor of the bone or soft tissue. E. It is a malignant tumor of the bone or soft tissue.\nWhich of the following is not a feature of Ewing sarcoma? A. It is a malignant tumor of bone or soft tissue. B. It is a tumor of the bone or soft tissue. C. It is a malignant tumor of the bone or soft tissue. D. It is a tumor of the bone or soft tissue. E. It is a malignant tumor of the bone or soft tissue.\nWhich of the following is not a feature of Ewing sarcoma? A. It is a malignant tumor of bone or soft tissue. B. It is a tumor of the bone or soft tissue. C. It is a malignant tumor of the bone or soft tissue. D. It is a tumor of the bone or soft tissue. E."
  },
  {
    "id": 40,
    "user_query": "Treatment of which disease was investigated in the MR CLEAN study?",
    "llama-2-7b-hf_response": "A. Alzheimer’s disease\nB. Parkinson’s disease\nC. Multiple sclerosis\nD. Amyotrophic lateral sclerosis\nE. Huntington’s disease\nThe correct answer is: A. Alzheimer’s disease\nThe MR CLEAN study was a randomized, double-blind, placebo-controlled trial that investigated the effect of intravenous immunoglobulin (IVIG) on the progression of Alzheimer’s disease. The study was conducted in the Netherlands and involved 220 patients with mild to moderate Alzheimer’s disease. The patients were randomly assigned to receive either IVIG or placebo every 4 weeks for a period of 12 months. The primary outcome measure was the change in the Mini-Mental State Examination (MMSE) score from baseline to 12 months. The MMSE is a standardized test used to assess cognitive function in patients with Alzheimer’s disease.\nThe results of the MR CLEAN study showed that IVIG did not significantly improve cognitive function in patients with Alzheimer’s disease. The MMSE score did not significantly differ between the IVIG and placebo groups at 12 months. The study also found that IVIG was well-tolerated and did not cause any serious adverse events.\nThe MR CLEAN study was an important step in the search for effective treatments for Alzheimer’s disease. While IVIG did not significantly improve cognitive function in this study, it is still being investigated as a potential treatment for Alzheimer’s disease.\nWhat is the name of the study that investigated the effect of intravenous immunoglobulin (IVIG) on the progression of Alzheimer’s disease?\nA. MR CLEAN\nB. MR CLEAN II\nC. MR CLEAN III\nD. MR CLEAN IV\nE. MR CLEAN V\nThe correct answer is: A. MR CLEAN\nThe MR CLEAN study was a randomized, double-blind, placebo-controlled trial that investigated the effect of intravenous immunoglobulin (IVIG) on the progression of Alzheimer’s disease. The study was conducted in the Netherlands"
  },
  {
    "id": 44,
    "user_query": "Does BNP increase after intensive exercise in athletes?",
    "llama-2-7b-hf_response": "Athletes are known to have a higher BNP than non-athletes. This is thought to be due to the increased cardiac output and blood volume associated with exercise. However, it is not clear if this increase is due to training or to the natural increase in BNP that occurs with age.\nIn this study, we compared the BNP levels of athletes and non-athletes before and after an intensive exercise session. We found that the BNP levels of athletes increased significantly after exercise, while the BNP levels of non-athletes did not change. This suggests that the increase in BNP after exercise is due to training, and not to the natural increase in BNP that occurs with age.\n1 Does BNP increase with exercise?\n2 Does BNP increase with age?\n3 Does BNP increase with heart failure?\n4 Does BNP increase with heart disease?\n5 Does BNP increase with hypertension?\n6 Does BNP increase with kidney disease?\n7 Does BNP increase with liver disease?\n8 Does BNP increase with lung disease?\n9 Does BNP increase with obesity?\n10 Does BNP increase with pregnancy?\n11 Does BNP increase with stress?\n12 Does BNP increase with thyroid disease?\n13 Does BNP increase with weight loss?\n14 Does BNP increase with weight gain?\n15 Does BNP increase with diabetes?\n16 Does BNP increase with cancer?\n17 Does BNP increase with COPD?\n18 Does BNP increase with depression?\n19 Does BNP increase with anxiety?\n20 Does BNP increase with Alzheimer’s disease?\n21 Does BNP increase with Parkinson’s disease?\n22 Does BNP increase with stroke?\n23 Does BNP increase with heart attack?\n24 Does BNP increase with heart failure?\n25 Does BNP increase with heart attack?\n26 Does BNP increase with heart failure?\n27 Does BNP increase with heart attack?\n28 Does BNP increase with heart attack?\n29 Does BNP increase with heart attack?\n30 Does BNP increase with heart attack?\n31 Does BNP increase with heart attack?\n32 Does BNP increase with heart attack?\n33 Does BNP"
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-hf_response": "Is Weaver syndrome a form of Down syndrome?\nWhat is Weaver syndrome?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in adults?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in adults?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in adults?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in adults?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in adults?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver syndrome in children?\nWhat is Weaver syndrome in babies?\nWhat is Weaver synd"
  },
  {
    "id": 49,
    "user_query": "Are ultraconserved elements often transcribed?",
    "llama-2-7b-hf_response": "A recent paper by K. K. Kumar et al. (2012) in Nature Genetics has been getting a lot of attention. The paper is titled \"Ultraconserved elements are transcribed in the human genome\" and it is available here.\nThe paper is about ultraconserved elements (UCEs), which are defined as \"sequences that are conserved across the human and chimpanzee genomes and are present in at least 99% of the human genome.\" The authors used RNA-Seq to identify UCEs that are transcribed in the human genome. They found 1,000 UCEs that are transcribed in the human genome.\nThe authors conclude that \"UCEs are transcribed in the human genome and may play a role in regulating gene expression.\"\nThe paper has been widely covered in the media, including in The New York Times, The Washington Post, and The Guardian.\nThe paper has also been criticized by some scientists, who argue that the data do not support the authors' conclusions.\nThe paper has been praised by some scientists, who argue that the data do support the authors' conclusions.\nThe paper has been criticized by some scientists, who argue that the data do not support the authors' conclusions.\nThe paper has been praised by some scientists, who argue that the data do support the authors' conclusions.\nThe paper has been criticized by some scientists, who argue that the data do not support the authors' conclusions.\nThe paper has been praised by some scientists, who argue that the data do support the authors' conclusions.\nThe paper has been criticized by some scientists, who argue that the data do not support the authors' conclusions.\nThe paper has been praised by some scientists, who argue that the data do support the authors' conclusions.\nThe paper has been criticized by some scientists, who argue that the data do not support the authors' conclusions.\nThe paper has been praised by some scientists, who argue that the data do support the authors' conclusions.\nThe paper has been criticized by some scientists, who argue that the data do not support the authors' conclusions.\nThe paper has been praised by some scientists, who argue that the data do support the"
  },
  {
    "id": 54,
    "user_query": "Which DNA sequences are more prone for the formation of R-loops?",
    "llama-2-7b-hf_response": "A recent study by the group of Dr. Javier Martinez-Pastor at the University of Valencia (Spain) has shown that the formation of R-loops is favored by the presence of a specific DNA sequence.\nR-loops are DNA structures formed by the interaction of two DNA strands, one of which is displaced from the nucleosome. They are formed in response to DNA damage and are involved in the repair of DNA double-strand breaks.\nThe study, published in the journal Nucleic Acids Research, used a computational approach to identify the DNA sequences that are more prone to form R-loops. The researchers found that the presence of a specific sequence, known as the R-loop motif, was associated with an increased risk of R-loop formation.\nThe R-loop motif is a short sequence of DNA bases that is present in many genes. It is composed of a G-C base pair followed by a C-G base pair. The presence of this motif in the DNA sequence increases the probability of R-loop formation.\nThe study found that the R-loop motif was present in the DNA sequences of many genes that are involved in the repair of DNA double-strand breaks. This suggests that the R-loop motif may play a role in the repair of DNA damage.\nThe study also found that the R-loop motif was present in the DNA sequences of many genes that are involved in the regulation of gene expression. This suggests that the R-loop motif may play a role in the regulation of gene expression.\nThe study found that the R-loop motif was present in the DNA sequences of many genes that are involved in the regulation of cell proliferation. This suggests that the R-loop motif may play a role in the regulation of cell proliferation.\nThe study found that the R-loop motif was present in the DNA sequences of many genes that are involved in the regulation of cell differentiation. This suggests that the R-loop motif may play a role in the regulation of cell differentiation.\nThe study found that the R-loop motif was present in the DNA sequences of many genes that are involved in the regulation of cell death. This suggests that the R-loop motif may play a role in the regulation of cell death.\nThe"
  },
  {
    "id": 55,
    "user_query": "Mutation of which gene is implicated in the familial isolated pituitary adenoma?",
    "bloom-7b1_response": "\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited.\n↑ \"ADH (Adrenocorticotropic Hormone)\", www.pituitary.org, Retrieved 2018-12-20. Edited"
  },
  {
    "id": 56,
    "user_query": "which mutations of troponin C gene have been found to cause hypertrophic cardiomyopathy?",
    "bloom-7b1_response": "\"\nThe answer is that the mutations of the troponin C gene are not the cause of hypertrophic cardiomyopathy. The cause of hypertrophic cardiomyopathy is the mutation of the myosin binding protein C gene. The myosin binding protein C gene is located on chromosome 17q21.3. The mutation of the myosin binding protein C gene causes the abnormal expression of the myosin binding protein C protein. The abnormal expression of the myosin binding protein C protein causes the abnormal contraction of the heart muscle. The abnormal contraction of the heart muscle causes the heart muscle to become enlarged. The enlarged heart muscle causes the heart to become weak and unable to pump blood to the body. The weak and unable to pump blood to the body causes the body to become weak and unable to perform normal functions. The weak and unable to perform normal functions causes the patient to become weak and unable to perform normal activities. The weak and unable to perform normal activities causes the patient to become weak and unable to perform normal work. The weak and unable to perform normal work causes the patient to become weak and unable to perform normal activities. The weak and unable to perform normal activities causes the patient to become weak and unable to perform normal work. The weak and unable to perform normal work causes the patient to become weak and unable to perform normal activities. The weak and unable to perform normal activities causes the patient to become weak and unable to perform normal work. The weak and unable to perform normal work causes the patient to become weak and unable to perform normal activities. The weak and unable to perform normal activities causes the patient to become weak and unable to perform normal work. The weak and unable to perform normal work causes the patient to become weak and unable to perform normal activities. The weak and unable to perform normal activities causes the patient to become weak and unable to perform normal work. The weak and unable to perform normal work causes the patient to become weak and unable to perform normal activities. The weak and unable to perform normal activities causes the patient to become weak and unable to perform normal work. The weak and unable to perform normal work causes the patient to become weak and unable to perform normal activities. The weak and unable to perform normal activities causes the patient to become weak and unable to perform normal work. The weak and unable to perform normal work causes the patient to become weak and unable to perform normal activities. The weak and unable to perform normal activities causes the patient to become weak and unable to perform normal work. The weak and unable to perform normal work causes the patient"
  },
  {
    "id": 58,
    "user_query": "Which post-translational histone modifications are characteristic of constitutive heterochromatin?",
    "bloom-7b1_response": "The answer to this question is not clear. In the case of the centromeric region of the human chromosome 1, the histone H3 lysine 9 trimethylation (H3K9me3) is a hallmark of constitutive heterochromatin (Lachner et al., 1999) . However, in the case of the centromeric region of the human chromosome Y, the histone H3 lysine 9 dimethylation (H3K9me2) is a hallmark of constitutive heterochromatin (Lachner et al., 1999) . In the case of the centromeric region of the human chromosome X, the histone H3 lysine 9 monomethylation (H3K9me1) is a hallmark of constitutive heterochromatin (Lachner et al., 1999) . In the case of the centromeric region of the human chromosome 4, the histone H3 lysine 9 acetylation (H3K9ac) is a hallmark of constitutive heterochromatin (Lachner et al., 1999) . In the case of the centromeric region of the human chromosome 5, the histone H3 lysine 9 dimethylation (H3K9me2) is a hallmark of constitutive heterochromatin (Lachner et al., 1999) . In the case of the centromeric region of the human chromosome 6, the histone H3 lysine 9 trimethylation (H3K9me3) is a hallmark of constitutive heterochromatin (Lachner et al., 1999) . In the case of the centromeric region of the human chromosome 7, the histone H3 lysine 9 dimethylation (H3K9me2) is a hallmark of constitutive heterochromatin (Lachner et al., 1999) . In the case of the centromeric region of the human chromosome 8, the histone H3 lysine 9 trimethylation (H3K9me3) is a hallmark of constitutive heterochromatin (Lachner et al., 1999) . In the case of the centromeric region of the human chromosome 9, the histone H3 lysine 9 dimethylation (H3K9me2) is a hallmark of constitutive heterochromatin (Lachner et al., 1999) . In the case of the centromeric region of the human chromosome 10, the histone H3 lysine 9 trimethylation (H3K9me3) is a hallmark of constitutive heterochromatin ("
  },
  {
    "id": 63,
    "user_query": "Are long non coding RNAs as conserved in sequence as protein coding genes?",
    "bloom-7b1_response": "The answer is yes. The first evidence for this was the discovery of the first long non coding RNA, the H19 imprinted gene, in the mouse (1) . The H19 gene is located on chromosome 11p15.5 and is transcribed from two different promoters, one of which is active in the placenta and the other in the liver. The H19 gene is transcribed into a long non coding RNA that is processed into two different transcripts, one of which is a long non coding RNA and the other is a microRNA. The long non coding RNA is processed into a microRNA and a protein. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The microRNA is processed into a protein that is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The microRNA is processed into a protein that is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is involved in the regulation of imprinting. The protein is a component of the PRC2 complex and is"
  },
  {
    "id": 65,
    "user_query": "What is clathrin?",
    "bloom-7b1_response": "Clathrin is a protein that is found in the cell membrane. It is a large protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clathrin coat is a protein that is found on the cell membrane. It is a protein that is made up of many different subunits. The clath"
  },
  {
    "id": 66,
    "user_query": "What are the main results of PRKAR1A Knockdown?",
    "bloom-7b1_response": "PRKAR1A Knockdown in the heart reduces the expression of genes involved in the regulation of cardiac hypertrophy and fibrosis, such as ANP, BNP, and TGF-β1. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac contractility, such as SERCA2a, and genes involved in the regulation of cardiac metabolism, such as PGC-1α and PPAR-γ. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac apoptosis, such as Bax and caspase-3. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac inflammation, such as NF-κB and TNF-α. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac fibrosis, such as collagen I and collagen III. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac hypertrophy, such as ANP, BNP, and TGF-β1. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac contractility, such as SERCA2a, and genes involved in the regulation of cardiac metabolism, such as PGC-1α and PPAR-γ. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac apoptosis, such as Bax and caspase-3. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac inflammation, such as NF-κB and TNF-α. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac fibrosis, such as collagen I and collagen III. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac hypertrophy, such as ANP, BNP, and TGF-β1. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac contractility, such as SERCA2a, and genes involved in the regulation of cardiac metabolism, such as PGC-1α and PPAR-γ. PRKAR1A Knockdown in the heart also reduces the expression of genes involved in the regulation of cardiac apoptosis, such as Bax and caspase-3. PRKAR1A Knockdown in the heart"
  },
  {
    "id": 72,
    "user_query": "Are transcribed ultraconserved regions involved in cancer?",
    "bloom-7b1_response": "The answer is yes, but only in a limited number of cases. The first example is the so-called 'telomere-associated' regions (TARs), which are located at the ends of chromosomes and are transcribed by RNA polymerase III. TARs are transcribed in a highly conserved manner and are thought to be involved in telomere maintenance (reviewed in [38] ). The second example is the so-called 'RNA polymerase III-associated' regions (RAPs), which are located at the ends of chromosomes and are transcribed by RNA polymerase III. RAPs are transcribed in a highly conserved manner and are thought to be involved in telomere maintenance (reviewed in [38] ). The third example is the so-called 'RNA polymerase II-associated' regions (RAPs), which are located at the ends of chromosomes and are transcribed by RNA polymerase II. RAPs are transcribed in a highly conserved manner and are thought to be involved in telomere maintenance (reviewed in [38] ). The fourth example is the so-called 'RNA polymerase III-associated' regions (RAPs), which are located at the ends of chromosomes and are transcribed by RNA polymerase III. RAPs are transcribed in a highly conserved manner and are thought to be involved in telomere maintenance (reviewed in [38] ). The fifth example is the so-called 'RNA polymerase II-associated' regions (RAPs), which are located at the ends of chromosomes and are transcribed by RNA polymerase II. RAPs are transcribed in a highly conserved manner and are thought to be involved in telomere maintenance (reviewed in [38] ). The sixth example is the so-called 'RNA polymerase III-associated' regions (RAPs), which are located at the ends of chromosomes and are transcribed by RNA polymerase III. RAPs are transcribed in a highly conserved manner and are thought to be involved in telomere maintenance (reviewed in [38] ). The seventh example is the so-called 'RNA polymerase II-associated' regions (RAPs), which are located at the ends of chromosomes and are transcribed by RNA polymerase II. RAPs are transcribed in a highly conserved manner and are thought to be involved in telomere maintenance (reviewed in [38] ). The eighth example is the so-called 'RNA polymerase III-associated' regions (RAPs), which are located at the ends of chromosomes and are transcribed by RNA polymerase III. RAPs are transcribed in"
  },
  {
    "id": 75,
    "user_query": "List side effects of SGLT2 inhibitors?",
    "bloom-7b1_response": "The most common side effects of SGLT2 inhibitors are gastrointestinal, including diarrhea, nausea, vomiting, and abdominal pain. These side effects are usually mild and resolve with continued use of the drug. However, in some patients, these side effects can be severe and require discontinuation of the drug. In addition, SGLT2 inhibitors can cause fluid retention, which can lead to edema and hypertension. In rare cases, SGLT2 inhibitors can cause kidney failure and death."
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "bloom-7b1_response": "*\n * @author Alexei Drummond\n * @author Andrew Rambaut\n * @author Alexei Drummond\n * @version $Id: JASPARRelease.java,v 1.1.1.1 2010/09/24 20:25:58 rambaut Exp $\n */\npublic class JASPARRelease {\n    private static final String VERSION = \"1.0\";\n    private static final String DATE = \"2010-09-24\";\n    private static final String URL = \"http://jaspar.genereg.net/\";\n    private static final String NAME = \"JASPAR\";\n    private static final String DESCRIPTION = \"JASPAR: a database of regulatory elements and their associated genes.\";\n    private static final String AUTHORS = \"Alexei Drummond, Andrew Rambaut, and Marc J. Borkowski\";\n    private static final String LICENSE = \"GNU GPL\";\n    private static final String RELEASE_DATE = DATE;\n    private static final String RELEASE_NAME = NAME;\n    private static final String RELEASE_DESCRIPTION = DESCRIPTION;\n    private static final String RELEASE_AUTHORS = AUTHORS;\n    private static final String LICENSE_NAME = LICENSE;\n    private static final String LICENSE_DESCRIPTION = LICENSE;\n    private static final String LICENSE_LINK = \"http://gnu.org/licenses/gpl.html\";\n    private static final String LICENSE_LICENSE = LICENSE_NAME;\n    private static final String LICENSE_LICENSE_DESCRIPTION = LICENSE_DESCRIPTION;\n    private static final String LICENSE_LICENSE_LINK = LICENSE_LINK;\n    private static final String LICENSE_LICENSE_DESCRIPTION = LICENSE_LICENSE_DESCRIPTION;\n    private static final String LICENSE_LICENSE_LINK = LICENSE_LICENSE_LINK;\n    private static final String LICENSE_LICENSE_DESCRIPTION = LICENSE_LICENSE_DESCRIPTION;\n    private static final String LICENSE_LICENSE_LINK = LICENSE_LICENSE_LINK;\n    private static final String LICENSE_LICENSE_DESCRIPTION = LICENSE_LICENSE_DESCRIPTION;\n    private static final String LICENSE_LICENSE_LINK = LICENSE_LICENSE_LINK;\n    private static final String LICENSE_LICENSE_DESCRIPTION = LICENSE_LICENSE_DESCRIPTION;\n    private static final String LICENSE_LICENSE_LINK = LICENSE_LICENSE_LINK;\n    private static final String LICENSE_LICENSE_DESCRIPTION = LICENSE_LICENSE_DESCRIPTION;\n    private static final String LICENSE_LICENSE_LINK = LICENSE_LICENSE_LINK;\n    private static final String LICENSE_LICENSE_DESCRIPTION = LICENSE_LICENSE_DESCRIPTION;\n    private static final String LICENSE_LICENSE_LINK = LICENSE_LICENSE_LINK;\n    private static final String LICENSE_LICENSE_DES"
  },
  {
    "id": 83,
    "user_query": "Which gene is required for the efficient function of clopidogrel?",
    "bloom-7b1_response": "The answer to this question is not known. The clopidogrel resistance is not due to the lack of the CYP2C19 enzyme, which is the main enzyme responsible for the metabolism of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is the main transporter of clopidogrel. The clopidogrel resistance is not due to the lack of the P-glycoprotein, which is"
  },
  {
    "id": 86,
    "user_query": "Which antibiotics target peptidoglycan biosynthesis?",
    "bloom-7b1_response": "The first antibiotic to be discovered was penicillin, which targets the bacterial cell wall. Penicillin inhibits the enzyme transpeptidase, which is responsible for the cross-linking of peptidoglycan. The second antibiotic to be discovered was streptomycin, which targets the enzyme transglycosylase, which is responsible for the addition of sugars to the peptidoglycan. The third antibiotic to be discovered was tetracycline, which targets the enzyme transpeptidase. The fourth antibiotic to be discovered was chloramphenicol, which targets the enzyme transglycosylase. The fifth antibiotic to be discovered was erythromycin, which targets the enzyme transpeptidase. The sixth antibiotic to be discovered was rifampicin, which targets the enzyme transpeptidase. The seventh antibiotic to be discovered was vancomycin, which targets the enzyme transglycosylase. The eighth antibiotic to be discovered was linezolid, which targets the enzyme transpeptidase. The ninth antibiotic to be discovered was daptomycin, which targets the enzyme transpeptidase. The tenth antibiotic to be discovered was quinupristin-dalfopristin, which targets the enzyme transpeptidase. The eleventh antibiotic to be discovered was tigecycline, which targets the enzyme transpeptidase. The twelfth antibiotic to be discovered was minocycline, which targets the enzyme transpeptidase. The thirteenth antibiotic to be discovered was clindamycin, which targets the enzyme transpeptidase. The fourteenth antibiotic to be discovered was rifabutin, which targets the enzyme transpeptidase. The fifteenth antibiotic to be discovered was rifampin, which targets the enzyme transpeptidase. The sixteenth antibiotic to be discovered was rifabutin, which targets the enzyme transpeptidase. The seventeenth antibiotic to be discovered was rifampin, which targets the enzyme transpeptidase. The eighteenth antibiotic to be discovered was rifampin, which targets the enzyme transpeptidase. The nineteenth antibiotic to be discovered was rifampin, which targets the enzyme transpeptidase. The twentieth antibiotic to be discovered was rifampin, which targets the enzyme transpeptidase. The twenty-first antibiotic to be discovered was rifampin, which targets the enzyme transpeptidase. The twenty-second antibiotic to be discovered was rifampin, which targets the enzyme transpept"
  },
  {
    "id": 92,
    "user_query": "What is the mode of action of everolimus?",
    "bloom-7b1_response": "Everolimus is a macrocyclic lactone that inhibits the mammalian target of rapamycin (mTOR) pathway. mTOR is a serine/threonine kinase that is activated by growth factors and is involved in cell growth, proliferation, and survival. Everolimus inhibits mTOR by binding to the mTOR kinase domain and preventing its activation. Everolimus is approved for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced breast cancer who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced gastrointestinal stromal tumors (GIST) who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced soft tissue sarcoma who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced pancreatic cancer who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced prostate cancer who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced breast cancer who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced gastrointestinal stromal tumors (GIST) who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced soft tissue sarcoma who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced pancreatic cancer who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced prostate cancer who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced breast cancer who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced gastrointestinal stromal tumors (GIST) who have failed prior therapy. Everolimus is also approved for the treatment of patients with advanced soft tissue sarcoma who have"
  },
  {
    "id": 97,
    "user_query": "Which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM)?",
    "bloom-7b1_response": ""
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "bloom-7b1_response": "The KP4 protein is a small, basic protein of about 20 kDa that is expressed in the cytoplasm of infected cells. It is not known whether KP4 is a structural component of the virion or a virion-associated protein. The KP4 protein is not essential for viral replication in tissue culture, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral entry into cells, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral assembly, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP4 protein is not required for viral RNA synthesis, but it is required for efficient viral replication in vivo. The KP"
  },
  {
    "id": 101,
    "user_query": "What is the principle of the PAR-CLIP methodology?",
    "bloom-7b1_response": "The PAR-CLIP method is based on the observation that the PARylation of a protein is a dynamic process. The PARylation of a protein is a reversible process, and the PARylation of a protein can be removed by PARG. Therefore, the PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PARylation of a protein can be detected by the PARylation of the protein in the presence of PARG. The PAR"
  },
  {
    "id": 106,
    "user_query": "Which package is available for analysing genomic interactions in R/Bioconductor?",
    "bloom-7b1_response": "\", function(answer) {\n    if (answer == \"package\") {\n      var package = require(\"r-cran.r-project.org/src/contrib/stats/glmnet\");\n      console.log(package);\n    }\n  });\n});\n// Load the package\nrequire(\"r-cran.r-project.org/src/contrib/stats/glmnet\");\n// Run the analysis\nvar glmnet = require(\"r-cran.r-project.org/src/contrib/stats/glmnet\");\nvar data = require(\"r-cran.r-project.org/src/contrib/stats/glmnet/data\");\nvar model = glmnet.glmnet(data, \"glmnet\");\nconsole.log(model);\n// Save the model\nvar modelFile = \"model.txt\";\nfs.writeFile(modelFile, JSON.stringify(model, null, 4), function(err) {\n  if (err) {\n    console.log(err);\n  } else {\n    console.log(\"Model saved to \" + modelFile);\n  }\n});\n// Run the analysis\nvar glmnet = require(\"r-cran.r-project.org/src/contrib/stats/glmnet\");\nvar data = require(\"r-cran.r-project.org/src/contrib/stats/glmnet/data\");\nvar model = glmnet.glmnet(data, \"glmnet\");\nconsole.log(model);\n// Save the model\nvar modelFile = \"model.txt\";\nfs.writeFile(modelFile, JSON.stringify(model, null, 4), function(err) {\n  if (err) {\n    console.log(err);\n  } else {\n    console.log(\"Model saved to \" + modelFile);\n  }\n});\n// Run the analysis\nvar glmnet = require(\"r-cran.r-project.org/src/contrib/stats/glmnet\");\nvar data = require(\"r-cran.r-project.org/src/contrib/stats/glmnet/data\");\nvar model = glmnet.glmnet(data, \"glmnet\");\nconsole.log(model);"
  },
  {
    "id": 107,
    "user_query": "How many clinical trials for off-label drugs in neonates are cited in the literature.",
    "bloom-7b1_response": "The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label drugs in neonates is shown in Table 1 . The number of clinical trials for off-label"
  },
  {
    "id": 112,
    "user_query": "What kind of affinity purification would you use in order to isolate soluble lysosomal proteins?",
    "bloom-7b1_response": "What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to purify lysosomal proteins? What would be the best method to pur"
  },
  {
    "id": 113,
    "user_query": "Which are the genes thought to be regulated by EWS/FLI?",
    "bloom-7b1_response": "What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of action of EWS/FLI? What are the mechanisms of"
  },
  {
    "id": 115,
    "user_query": "Which pathological conditions are caused by mutations in the CYLD gene?",
    "bloom-7b1_response": "CYLD is a negative regulator of the NF-κB pathway. The NF-κB pathway is activated in many pathological conditions, including cancer, autoimmune diseases, and inflammatory diseases. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κB pathway. CYLD is a negative regulator of the NF-κ"
  },
  {
    "id": 121,
    "user_query": "List genes that have been found mutated in CMT1A (Charcot-Marie-Tooth disease type 1 A).",
    "bloom-7b1_response": "The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the order of their discovery. The genes are listed in the"
  },
  {
    "id": 123,
    "user_query": "Which genes have been associated with Cerebral Cavernous Malformation?",
    "bloom-7b1_response": "\", www.ncbi.nlm.nih.gov/pubmed, accessed on May, 2017). The most common genetic cause of CVM is the mutation of the NOTCH1 gene, which is located on chromosome 17q25.1. The NOTCH1 gene encodes a transmembrane receptor that is activated by the binding of a ligand. The NOTCH1 gene is expressed in the vascular endothelial cells and smooth muscle cells of the cerebral arteries. The NOTCH1 gene mutation is associated with the development of CVM. The NOTCH1 gene mutation is also associated with the development of other vascular malformations, such as arteriovenous malformations (AVMs), cavernous hemangiomas, and capillary malformations. The NOTCH1 gene mutation is also associated with the development of other vascular malformations, such as arteriovenous malformations (AVMs), cavernous hemangiomas, and capillary malformations. The NOTCH1 gene mutation is also associated with the development of other vascular malformations, such as arteriovenous malformations (AVMs), cavernous hemangiomas, and capillary malformations. The NOTCH1 gene mutation is also associated with the development of other vascular malformations, such as arteriovenous malformations (AVMs), cavernous hemangiomas, and capillary malformations. The NOTCH1 gene mutation is also associated with the development of other vascular malformations, such as arteriovenous malformations (AVMs), cavernous hemangiomas, and capillary malformations. The NOTCH1 gene mutation is also associated with the development of other vascular malformations, such as arteriovenous malformations (AVMs), cavernous hemangiomas, and capillary malformations. The NOTCH1 gene mutation is also associated with the development of other vascular malformations, such as arteriovenous malformations (AVMs), cavernous hemangiomas, and capillary malformations. The NOTCH1 gene mutation is also associated with the development of other vascular malformations, such as arteriovenous malformations (AVMs), cavernous hemangiomas, and capillary malformations. The NOTCH1 gene mutation is also associated with the development of other vascular malformations, such as arteriovenous malformations (AVMs), cavernous"
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "bloom-7b1_response": "? DITPA is a synthetic analog of thyroxine (T4) that is structurally similar to T4 but lacks the iodine atom. DITPA is a pro-drug that is converted to the active form of T4 by the enzyme DITPA decarboxylase (DITPA-DC) in the thyroid gland. DITPA-DC is a member of the family of cytochrome P450 enzymes, which are involved in the metabolism of a variety of endogenous and exogenous compounds. DITPA-DC is expressed in the thyroid gland and is also expressed in the liver, kidney, and intestine. DITPA-DC is a member of the cytochrome P450 family of enzymes, which are involved in the metabolism of a variety of endogenous and exogenous compounds. DITPA-DC is expressed in the thyroid gland and is also expressed in the liver, kidney, and intestine. DITPA-DC is a member of the cytochrome P450 family of enzymes, which are involved in the metabolism of a variety of endogenous and exogenous compounds. DITPA-DC is expressed in the thyroid gland and is also expressed in the liver, kidney, and intestine. DITPA-DC is a member of the cytochrome P450 family of enzymes, which are involved in the metabolism of a variety of endogenous and exogenous compounds. DITPA-DC is expressed in the thyroid gland and is also expressed in the liver, kidney, and intestine. DITPA-DC is a member of the cytochrome P450 family of enzymes, which are involved in the metabolism of a variety of endogenous and exogenous compounds. DITPA-DC is expressed in the thyroid gland and is also expressed in the liver, kidney, and intestine. DITPA-DC is a member of the cytochrome P450 family of enzymes, which are involved in the metabolism of a variety of endogenous and exogenous compounds. DITPA-DC is expressed in the thyroid gland and is also expressed in the liver, kidney, and intestine. DITPA-DC is a member of the cytochrome P450 family of enzymes, which are involved in the metabolism of a variety of endogenous and exogenous compounds. DITPA-DC is expressed in the thyroid gland and is also expressed in the liver, kidney, and intestine. DITPA-DC is a member of the cyto"
  },
  {
    "id": 130,
    "user_query": "What is needed for MMP proteins to be functional?",
    "bloom-7b1_response": "The answer to this question is not clear. It is possible that the MMP proteins are not active in the absence of a specific activator. Alternatively, the MMP proteins may be active in the absence of a specific activator, but the activator is not present in the tissue. In this case, the MMP proteins would be inactive in the tissue. The MMP proteins may be active in the absence of a specific activator, but the activator is present in the tissue at a concentration that is too low to be detected by the assay used in this study. In this case, the MMP proteins would be active in the tissue, but the activator would not be detected by the assay used in this study. The MMP proteins may be active in the absence of a specific activator, but the activator is present in the tissue at a concentration that is too high to be detected by the assay used in this study. In this case, the MMP proteins would be active in the tissue, but the activator would be detected by the assay used in this study. The MMP proteins may be active in the absence of a specific activator, but the activator is present in the tissue at a concentration that is too low to be detected by the assay used in this study. In this case, the MMP proteins would be active in the tissue, but the activator would be detected by the assay used in this study. The MMP proteins may be active in the absence of a specific activator, but the activator is present in the tissue at a concentration that is too high to be detected by the assay used in this study. In this case, the MMP proteins would be active in the tissue, but the activator would be detected by the assay used in this study. The MMP proteins may be active in the absence of a specific activator, but the activator is present in the tissue at a concentration that is too low to be detected by the assay used in this study. In this case, the MMP proteins would be active in the tissue, but the activator would be detected by the assay used in this study. The MMP proteins may be active in the absence of a specific activator, but the activator is present in the tissue at a concentration that is too high to be detected by the assay used in this study. In this case, the MMP proteins would be active in the tissue, but the activator would be detected by the assay used in this study."
  },
  {
    "id": 133,
    "user_query": "Which is the most known bacterium responsible for botulism (sausage-poisoning)?",
    "bloom-7b1_response": "A. Clostridium botulinum B. Clostridium tetani C. Clostridium perfringens D. Clostridium sporogenes E. Clostridium novyi F. Clostridium butyricum G. Clostridium tyrobutyricum H. Clostridium welchii I. Clostridium butyricum\nThe most common cause of food poisoning is A. Listeria monocytogenes. B. Salmonella enterica serovar Typhi C. Salmonella enterica serovar Paratyphi A D. Shigella dysenteriae E. Shigella flexneri F. Shigella sonnei G. Shigella boydii H. Shigella flexneri I. Shigella dysenteriae\nWhich of the following is the most common cause of food poisoning? A. Salmonella enterica serovar Typhi B. Salmonella enterica serovar Paratyphi A C. Shigella dysenteriae D. Shigella flexneri E. Shigella sonnei F. Shigella boydii G. Shigella flexneri H. Shigella dysenteriae I. Shigella dysenteriae\nWhich of the following is the most common cause of food poisoning? A. Salmonella enterica serovar Typhi B. Salmonella enterica serovar Paratyphi A C. Shigella dysenteriae D. Shigella flexneri E. Shigella sonnei F. Shigella boydii G. Shigella flexneri H. Shigella dysenteriae I. Shigella dysenteriae\nWhich of the following is the most common cause of food poisoning? A. Salmonella enterica serovar Typhi B. Salmonella enterica serovar Paratyphi A C. Shigella dysenteriae D. Shigella flexneri E. Shigella sonnei F. Shigella boydii G. Shigella flexneri H. Shigella dysenteriae I. Shigella dysenteriae\nWhich of the following is the most common cause of food poisoning? A. Salmonella enterica serovar Typhi B. Salmonella enterica serovar Paratyphi A C. Shigella dysenteriae D. Shigella flexneri E. Shigella sonnei F. Shig"
  },
  {
    "id": 138,
    "user_query": "Which are the plant DNA (cytosine-5) methyltransferase families?",
    "bloom-7b1_response": "\", www.plantphysiol.org, 2004, vol. 155, no. 3, pp. 773–782. [40] M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R. Bender, M. J. R"
  },
  {
    "id": 139,
    "user_query": "Where is the histone variant CENPA preferentially localized?",
    "bloom-7b1_response": "We found that CENPA was preferentially localized to the centromere of the chromosome arms, but not to the centromere of the chromosome arms (Fig. 4A) . The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and the telomere. The centromere of the chromosome arms was defined as the region between the centromere and"
  },
  {
    "id": 140,
    "user_query": "In which proteins is the chromodomain present?",
    "bloom-7b1_response": "The chromodomain is present in the majority of proteins that bind DNA, including transcription factors, DNA repair proteins, and DNA replication proteins. The chromodomain is also present in proteins that bind RNA, including RNA polymerases, RNA helicases, and RNA-binding proteins. The chromodomain is also present in proteins that bind proteins, including histone acetyltransferases, histone deacetylases, and histone methyltransferases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain is also present in proteins that bind DNA, RNA, and proteins, including DNA repair proteins, DNA replication proteins, and RNA polymerases. The chromodomain"
  },
  {
    "id": 142,
    "user_query": "Is amiodarone a class I anti-arrhythmic drug?",
    "bloom-7b1_response": "Amiodarone is a class I anti-arrhythmic drug. It is a lipophilic drug that is highly bound to plasma proteins. It is metabolized in the liver by cytochrome P450 enzymes. It is a substrate for the P-glycoprotein transporter. It is a weak inhibitor of CYP3A4 and CYP2C9. It is a weak inhibitor of CYP2C19. It is a weak inhibitor of CYP2D6. It is a weak inhibitor of CYP1A2. It is a weak inhibitor of CYP2E1. It is a weak inhibitor of CYP1A1. It is a weak inhibitor of CYP2B6. It is a weak inhibitor of CYP2C8. It is a weak inhibitor of CYP2C9. It is a weak inhibitor of CYP2C19. It is a weak inhibitor of CYP2D6. It is a weak inhibitor of CYP3A4. It is a weak inhibitor of CYP2C8. It is a weak inhibitor of CYP2C9. It is a weak inhibitor of CYP2C19. It is a weak inhibitor of CYP2D6. It is a weak inhibitor of CYP3A4. It is a weak inhibitor of CYP2C8. It is a weak inhibitor of CYP2C9. It is a weak inhibitor of CYP2C19. It is a weak inhibitor of CYP2D6. It is a weak inhibitor of CYP3A4. It is a weak inhibitor of CYP2C8. It is a weak inhibitor of CYP2C9. It is a weak inhibitor of CYP2C19. It is a weak inhibitor of CYP2D6. It is a weak inhibitor of CYP3A4. It is a weak inhibitor of CYP2C8. It is a weak inhibitor of CYP2C9. It is a weak inhibitor of CYP2C19. It is a weak inhibitor of CYP2D6. It is a weak inhibitor of CYP3A4. It is a weak inhibitor of CYP2C8. It is a weak inhibitor of CYP2C9. It is a weak inhibitor of CYP2C19. It is a weak inhibitor of CYP2D6. It is a weak inhibitor of CYP3A4. It is a weak inhibitor of CYP2C8. It is a weak inhibitor of CYP2C9. It is a weak inhibitor of CYP2C19. It is a weak inhibitor of CYP"
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "bloom-7b1_response": "COUGER is a tool for the analysis of the structure of the genome. It is based on the concept of the COG (Clusters of Orthologous Groups of proteins) database. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is a collection of orthologous groups of proteins from different species. The COG database is"
  }
]